Here are five things to know about the acquisition:
1. The new products will enhance Integra’s lower extremity product offering.
2. Integra LifeSciences revenues were around $6 million in 2013, with double-digit growth over the prior year.
3. Integra LifeScience expects the acquisition to have a minimal impact on the company’s 2015 profits and slower growth during the transition period.
4. Long-term, Integra LifeSciences expects to return to double-digit growth.
5. Metasurg is known for several products, including the DigiFuse Cannulated Intramedullary Fusion System. Integra will now also offer Metasurg’s BioFix Regenerative Biologics product line.
More articles on orthopedic devices:
17 spine devices receive FDA 510(k) clearance in December
Amedica restructuring includes 28% staff reduction, new spine focus—5 key points
Bacterin revenue up for 5th consecutive quarter—5 things to know
